Astria Therapeutics (ATXS) News Today $9.55 -0.12 (-1.24%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Growth in Short InterestAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 3,150,000 shares, an increase of 8.6% from the November 15th total of 2,900,000 shares. Based on an average daily volume of 321,400 shares, the short-interest ratio is presently 9.8 days. Approximately 6.5% of the company's stock are short sold.December 15 at 4:12 PM | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 152.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 314,265 shares of the bioDecember 15 at 3:10 AM | marketbeat.comAstria Therapeutics’ Navenibart Shows Promising Results in HAE Prophylaxis, Earning Buy RatingDecember 12, 2024 | markets.businessinsider.comAstria Therapeutics price target raised to $32 from $28 at OppenheimerDecember 12, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS)December 12, 2024 | americanbankingnews.comAstria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAEDecember 11, 2024 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Fmr LLCFmr LLC raised its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 29.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,822,275 shares of the biotechnology company's stock afterDecember 6, 2024 | marketbeat.comRA Capital Management L.P. Has $56.21 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)RA Capital Management L.P. increased its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 1.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,105,213 shares of the biotechnology company's stocDecember 5, 2024 | marketbeat.comRedmile Group LLC Takes $3.42 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)Redmile Group LLC purchased a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the third quarter, according to its most recent filing with the SEC. The fund purchased 310,884 shares of the biotechnology company's stock, valued at approximately $3,423,000. Redmile Group LLC owneDecember 5, 2024 | marketbeat.comWalleye Capital LLC Buys 71,439 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Walleye Capital LLC raised its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 69.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 174,581 shares of the biotechnology company'sDecember 5, 2024 | marketbeat.comVestal Point Capital LP Acquires 750,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Vestal Point Capital LP grew its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 23.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 4,000,000 shares of the biotechnology company's stock after acquiring an additional 750,000 shareNovember 29, 2024 | marketbeat.comAstria Therapeutics: Transformative Proof Of Concept Data In Hereditary AngioedemaNovember 27, 2024 | seekingalpha.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from BrokeragesShares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have earned a consensus recommendation of "Buy" from the six research firms that are covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating toNovember 24, 2024 | marketbeat.comResearch Analysts Set Expectations for ATXS FY2024 EarningsAstria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Astria Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology cNovember 18, 2024 | marketbeat.comAstria Therapeutics Reports Q3 2024 Financial ResultsNovember 16, 2024 | tipranks.comAstria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNovember 15, 2024 | stockhouse.comAstria Therapeutics (NASDAQ:ATXS) Shares Down 5.3% - Time to Sell?Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3% - What's Next?November 15, 2024 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Astria Therapeutics (ATXS)November 14, 2024 | markets.businessinsider.comPromising Outlook for Astria Therapeutics: Strong Financials and Key Program Advancements Support Buy RatingNovember 14, 2024 | markets.businessinsider.comOppenheimer Remains a Buy on Astria Therapeutics (ATXS)November 14, 2024 | markets.businessinsider.comAstria Therapeutics (NASDAQ:ATXS) Shares Gap Up Following Analyst UpgradeAstria Therapeutics (NASDAQ:ATXS) Shares Gap Up After Analyst UpgradeNovember 14, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 at OppenheimerOppenheimer boosted their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a research report on Thursday.November 14, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Cross Above 50-Day Moving Average - What's Next?Astria Therapeutics (NASDAQ:ATXS) Shares Cross Above 50 Day Moving Average - Here's WhyNovember 7, 2024 | marketbeat.comAstria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific MeetingOctober 30, 2024 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from AnalystsAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been given a consensus recommendation of "Buy" by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a stronOctober 30, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Up 6.8% - Should You Buy?Astria Therapeutics (NASDAQ:ATXS) Trading 6.8% Higher - Here's WhyOctober 24, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Passes Below 50 Day Moving Average - Should You Sell?Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Below 50-Day Moving Average - Should You Sell?October 23, 2024 | marketbeat.comAstria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific MeetingOctober 21, 2024 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest UpdateAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 3,470,000 shares, a drop of 9.2% from the September 15th total of 3,820,000 shares. Approximately 7.3% of the company's stock are short sold. Based on an average daily volume of 381,000 shares, the short-interest ratio is currently 9.1 days.October 15, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1% - Should You Sell?Astria Therapeutics (NASDAQ:ATXS) Shares Down 4.1% - What's Next?October 14, 2024 | marketbeat.comDimensional Fund Advisors LP Acquires 133,379 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Dimensional Fund Advisors LP raised its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 1,043.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 146,158 shares of the biotechnologyOctober 13, 2024 | marketbeat.comCubist Systematic Strategies LLC Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS)Cubist Systematic Strategies LLC purchased a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 281,410 shares of the biotechnology company's stock, valued at approximately $2,October 12, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Up 5.2% - Here's What HappenedAstria Therapeutics (NASDAQ:ATXS) Stock Price Up 5.2% - Should You Buy?October 11, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Millennium Management LLCMillennium Management LLC increased its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 13.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,842,063 shares of the biotechnologOctober 6, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of "Buy" by BrokeragesShares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have received an average rating of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buyOctober 5, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1%Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1%October 2, 2024 | marketbeat.comLogos Global Management LP Sells 1,744,960 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Logos Global Management LP lowered its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 77.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 500,000 shares of the biotechnology company's stoOctober 1, 2024 | marketbeat.comAstria Gets FDA Orphan Designation for Navenibart in Hereditary AngioedemaSeptember 30, 2024 | marketwatch.comAstria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary AngioedemaSeptember 30, 2024 | finance.yahoo.comCubist Systematic Strategies LLC Invests $2.56 Million in Astria Therapeutics, Inc. (NASDAQ:ATXS)Cubist Systematic Strategies LLC purchased a new position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 281,410 shares of the biotechnology compaSeptember 30, 2024 | marketbeat.comEvercore ISI Sticks to Their Buy Rating for Astria Therapeutics (ATXS)September 27, 2024 | markets.businessinsider.comAstria Therapeutics to Present at Upcoming Global Angioedema ForumSeptember 27, 2024 | finance.yahoo.comAstria Therapeutics' (ATXS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Friday.September 27, 2024 | marketbeat.comAffinity Asset Advisors LLC Has $8.88 Million Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)Affinity Asset Advisors LLC boosted its position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 15.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 975,606 shares of the biotechnology company's stockSeptember 25, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Shares Sold by Logos Global Management LPLogos Global Management LP trimmed its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 77.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 500,000 shares of the biotechnology company's stock after selling 1,744,96September 24, 2024 | marketbeat.comAstria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology CongressSeptember 19, 2024 | businesswire.comSofinnova Investments Inc. Purchases New Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)Sofinnova Investments Inc. purchased a new position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 60,692 shares ofSeptember 17, 2024 | marketbeat.comClariVest Asset Management LLC Invests $731,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS)ClariVest Asset Management LLC bought a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 80,315 shares of the biotechnology company's stock, valued at apprSeptember 13, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Trading Down 5.9%Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 5.9%September 11, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Buy" from BrokeragesShares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to theSeptember 10, 2024 | marketbeat.com Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk threatens Liberal’s fake “energy crisis” (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now ATXS Media Mentions By Week ATXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATXS News Sentiment▼0.710.71▲Average Medical News Sentiment ATXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATXS Articles This Week▼72▲ATXS Articles Average Week Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Centessa Pharmaceuticals News Today Recursion Pharmaceuticals News Today Apogee Therapeutics News Today ImmunityBio News Today Wave Life Sciences News Today Mirum Pharmaceuticals News Today Akero Therapeutics News Today Tarsus Pharmaceuticals News Today Amphastar Pharmaceuticals News Today Disc Medicine News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATXS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
